当前位置: 首页 >> 检索结果
201. Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial.
作者: Justin A Ezekowitz.;Ciaran J McMullan.;Cynthia M Westerhout.;Ileana L Piña.;Jose Lopez-Sendon.;Kevin J Anstrom.;Adrian F Hernandez.;Carolyn S P Lam.;Christopher M O'Connor.;Burkert Pieske.;Piotr Ponikowski.;Lothar Roessig.;Adriaan A Voors.;Joerg Koglin.;Paul W Armstrong.;Javed Butler.; .
来源: Circ Heart Fail. 2023年16卷9期e010599页
We examined whether the primary composite outcome (cardiovascular death or heart failure hospitalization) was related to differences in background use and dosing of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction enrolled in VICTORIA (Vericiguat Global Study in Subjects with Heart Failure with Reduced Ejection Fraction), a randomized trial of vericiguat versus placebo.
202. Final 3-Year Outcomes of a Randomized Trial Comparing a Self-Expanding to a Balloon-Expandable Transcatheter Aortic Valve.
作者: Jonas Lanz.;Helge Möllmann.;Won-Keun Kim.;Christof Burgdorf.;Axel Linke.;Simon Redwood.;Michael Hilker.;Michael Joner.;Holger Thiele.;Lars Conzelmann.;Lenard Conradi.;Sebastian Kerber.;Christian Thilo.;Stefan Toggweiler.;Bernard Prendergast.;Oliver Husser.;Stefan Stortecky.;Sarah Deckarm.;Arnaud Künzi.;Dik Heg.;Thomas Walther.;Stephan Windecker.;Thomas Pilgrim.; .
来源: Circ Cardiovasc Interv. 2023年16卷7期e012873页
In the SCOPE I trial (Safety and Efficacy of the Symetis ACURATE Neo/TF Compared to the Edwards SAPIEN 3 Bioprosthesis), transcatheter aortic valve implantation with the self-expanding ACURATE neo (NEO) did not meet noninferiority compared with the balloon-expandable SAPIEN 3 (S3) device regarding a composite end point at 30 days due to higher rates of prosthetic valve regurgitation and acute kidney injury. Data on long-term durability of NEO are scarce. Here, we report whether early differences between NEO and S3 translate into differences in clinical outcomes or bioprosthetic valve failure 3 years after transcatheter aortic valve implantation.
203. Inhaled Epoprostenol Compared With Nitric Oxide for Right Ventricular Support After Major Cardiac Surgery.
作者: Kamrouz Ghadimi.;Jhaymie L Cappiello.;Mary Cooter Wright.;Jerrold H Levy.;Benjamin S Bryner.;Adam D DeVore.;Jacob N Schroder.;Chetan B Patel.;Sudarshan Rajagopal.;Svati H Shah.;Carmelo A Milano.; .
来源: Circulation. 2023年148卷17期1316-1329页
Right ventricular failure (RVF) is a leading driver of morbidity and death after major cardiac surgery for advanced heart failure, including orthotopic heart transplantation and left ventricular assist device implantation. Inhaled pulmonary-selective vasodilators, such as inhaled epoprostenol (iEPO) and nitric oxide (iNO), are essential therapeutics for the prevention and medical management of postoperative RVF. However, there is limited evidence from clinical trials to guide agent selection despite the significant cost considerations of iNO therapy.
204. Effect of the P-Selectin Inhibitor Crizanlizumab on Survival Free of Organ Support in Patients Hospitalized for COVID-19: A Randomized Controlled Trial.
作者: Scott D Solomon.;Charles J Lowenstein.;Ankeet S Bhatt.;Alexander Peikert.;Orly Vardeny.;Mikhail N Kosiborod.;Jeffrey S Berger.;Harmony R Reynolds.;Stephanie Mavromichalis.;Anya Barytol.;Andrew D Althouse.;James F Luther.;Eric S Leifer.;Andrei L Kindzelski.;Mary Cushman.;Michelle N Gong.;Lucy Z Kornblith.;Pooja Khatri.;Keri S Kim.;Lisa Baumann Kreuziger.;Lana Wahid.;Bridget-Anne Kirwan.;Mark W Geraci.;Matthew D Neal.;Judith S Hochman.; .
来源: Circulation. 2023年148卷5期381-390页
COVID-19 has been associated with endothelial injury, resultant microvascular inflammation and thrombosis. Activated endothelial cells release and express P-selectin and von Willebrand factor, both of which are elevated in severe COVID-19 and may be implicated in the disease pathophysiology. We hypothesized that crizanlizumab, a humanized monoclonal antibody to P-selectin, would reduce morbidity and death in patients hospitalized for COVID-19.
205. Cardiac Magnetic Resonance Imaging Versus Invasive-Based Strategies in Patients With Chest Pain and Detectable to Mildly Elevated Serum Troponin: A Randomized Clinical Trial.
作者: Chadwick D Miller.;Simon A Mahler.;Anna C Snavely.;Subha V Raman.;Jeffrey M Caterino.;Carol L Clark.;Alan E Jones.;Michael E Hall.;Lauren E Koehler.;James F Lovato.;Brian C Hiestand.;Jason P Stopyra.;Carolyn J Park.;Sujethra Vasu.;Michael A Kutcher.;W Gregory Hundley.
来源: Circ Cardiovasc Imaging. 2023年16卷6期e015063页
The optimal diagnostic strategy for patients with chest pain and detectable to mildly elevated serum troponin is not known. The objective was to compare clinical outcomes among an early decision for a noninvasive versus an invasive-based care pathway.
206. Prediction of Shock-Refractory Ventricular Fibrillation During Resuscitation of Out-of-Hospital Cardiac Arrest.
作者: Jason Coult.;Betty Y Yang.;Heemun Kwok.;J Nathan Kutz.;Patrick M Boyle.;Jennifer Blackwood.;Thomas D Rea.;Peter J Kudenchuk.
来源: Circulation. 2023年148卷4期327-335页
Out-of-hospital cardiac arrest due to shock-refractory ventricular fibrillation (VF) is associated with relatively poor survival. The ability to predict refractory VF (requiring ≥3 shocks) in advance of repeated shock failure could enable preemptive targeted interventions aimed at improving outcome, such as earlier administration of antiarrhythmics, reconsideration of epinephrine use or dosage, changes in shock delivery strategy, or expedited invasive treatments.
207. Effect of Torsemide Versus Furosemide on Symptoms and Quality of Life Among Patients Hospitalized for Heart Failure: The TRANSFORM-HF Randomized Clinical Trial.
作者: Stephen J Greene.;Eric J Velazquez.;Kevin J Anstrom.;Robert M Clare.;Tracy A DeWald.;Mitchell A Psotka.;Andrew P Ambrosy.;Gerin R Stevens.;John J Rommel.;Tamas Alexy.;Fassil Ketema.;Dong-Yun Kim.;Patrice Desvigne-Nickens.;Bertram Pitt.;Eric L Eisenstein.;Robert J Mentz.; .
来源: Circulation. 2023年148卷2期124-134页
Loop diuretics are a primary therapy for the symptomatic treatment of heart failure (HF), but whether torsemide improves patient symptoms and quality of life better than furosemide remains unknown. As prespecified secondary end points, the TRANSFORM-HF trial (Torsemide Comparison With Furosemide for Management of Heart Failure) compared the effect of torsemide versus furosemide on patient-reported outcomes among patients with HF.
208. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials.
作者: Michael E Nassif.;Sheryl L Windsor.;Kensey Gosch.;Barry A Borlaug.;Mansoor Husain.;Silvio E Inzucchi.;Dalane W Kitzman.;Darren K McGuire.;Bertram Pitt.;Benjamin M Scirica.;Sanjiv J Shah.;Guillermo Umpierrez.;Bethany A Austin.;Sumant Lamba.;Taiyeb Khumri.;Kavita Sharma.;Mikhail N Kosiborod.
来源: Circ Heart Fail. 2023年16卷7期e009837页
Patients with heart failure (HF) have a high burden of symptoms and physical limitations, regardless of ejection fraction (EF). Whether the benefits of SGLT2 (sodium-glucose cotransporter-2) inhibitors on these outcomes vary across the full range of EF remains unclear.
209. Reach Out Emergency Department: A Randomized Factorial Trial to Determine the Optimal Mobile Health Components to Reduce Blood Pressure.
作者: Lesli E Skolarus.;Mackenzie Dinh.;Kelley M Kidwell.;Chun Chieh Lin.;Lorraine R Buis.;Devin L Brown.;Rockefeller Oteng.;Michael Giacalone.;Kimberly Warden.;Deborah E Trimble.;Candace Whitfield.;Zahera Farhan.;Adam Flood.;Dominic Borgialli.;Sacha Montas.;Michael Jaggi.;William J Meurer.
来源: Circ Cardiovasc Qual Outcomes. 2023年16卷5期e009606页
Mobile health (mHealth) strategies initiated in safety-net Emergency Departments may be one approach to address the US hypertension epidemic, but the optimal mHealth components or dose are unknown.
210. Effects of Atrioventricular Optimization on Left Ventricular Reverse Remodeling With Cardiac Resynchronization Therapy: Results of the SMART-CRT Trial.
作者: Michael R Gold.;Kenneth A Ellenbogen.;Christophe Leclercq.;Jonathan Lowy.;Seth J Rials.;Morio Shoda.;Gery Tomassoni.;Ziad Issa.;Jean-Francois Sarrazin.;John M Jennings.;Devi G Nair.;Nicholas Wold.;Patrick Yong.;Michelle M Harbin.;Kenneth M Stein.;Angelo Auricchio.
来源: Circ Arrhythm Electrophysiol. 2023年16卷6期e011714页
The role of atrioventricular optimization (AVO) to improve cardiac resynchronization therapy outcomes remains controversial. Previous post hoc analyses of a multicenter trial showed that measures of electrical dyssynchrony (right ventricular-left ventricular [LV] or LV electrical delay durations) are associated with patients who benefit from AVO.
211. Economic Outcomes of Transcatheter Versus Surgical Aortic Valve Replacement in Patients with Severe Aortic Stenosis and Low Surgical Risk: Results from the PARTNER 3 Trial.
作者: Benjamin Z Galper.;Khaja M Chinnakondepalli.;Kaijun Wang.;Elizabeth A Magnuson.;Michael Lu.;Vinod H Thourani.;Susheel Kodali.;Raj Makkar.;Howard C Herrmann.;Samir Kapadia.;Mathew Williams.;John Webb.;Craig R Smith.;Michael J Mack.;Martin B Leon.;David J Cohen.; .
来源: Circulation. 2023年147卷21期1594-1605页
In patients with severe symptomatic aortic stenosis at low surgical risk, transfemoral transcatheter aortic valve replacement (TAVR) with the SAPIEN 3 valve has been shown to reduce the composite of death, stroke, or rehospitalization at 2-year follow-up compared with surgical aortic valve replacement (SAVR). Whether TAVR is cost-effective compared with SAVR for low-risk patients remains uncertain.
212. Rivaroxaban for Prevention of Thrombotic Events, Hospitalization, and Death in Outpatients With COVID-19: A Randomized Clinical Trial.
作者: Gregory Piazza.;Alex C Spyropoulos.;Judith Hsia.;Mark Goldin.;William J Towner.;Alan S Go.;Todd M Bull.;Stephen Weng.;Concetta Lipardi.;Elliot S Barnathan.;Marc P Bonaca.; .
来源: Circulation. 2023年147卷25期1891-1901页
COVID-19 (coronavirus disease 2019) is associated with heightened risks of venous and arterial thrombosis and hospitalization due to respiratory failure. To assess whether prophylactic anticoagulation can safely reduce the frequency of venous and arterial thrombosis, hospitalization, and death in nonhospitalized patients with symptomatic COVID-19 and at least one thrombosis risk factor, we conducted the PREVENT-HD double-blind, placebo-controlled randomized trial (A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic COVID-19] Infection).
213. Prognostic Importance of NT-proBNP (N-Terminal Pro-B-Type Natriuretic Peptide) Following High-Risk Myocardial Infarction in the PARADISE-MI Trial.
作者: Karola S Jering.;Brian L Claggett.;Marc A Pfeffer.;Christopher B Granger.;Lars Køber.;Eldrin F Lewis.;Aldo P Maggioni.;Douglas L Mann.;John J V McMurray.;Margaret F Prescott.;Jean L Rouleau.;Scott D Solomon.;Phillippe Gabriel Steg.;Dirk von Lewinski.;Eugene Braunwald.
来源: Circ Heart Fail. 2023年16卷5期e010259页
NT-proBNP (N-terminal pro-B-type natriuretic peptide) is a potent predictor of death and heart failure (HF) across multiple populations. We evaluated the prognostic importance of NT-proBNP in patients with acute myocardial infarction (MI) complicated by left ventricular systolic dysfunction, pulmonary congestion, or both and ≥1 of 8 risk-augmenting factors enrolled in the PARADISE-MI trial (Prospective ARNI vs ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After Myocardial Infarction).
214. Empagliflozin Improves Left Atrial Strain in Patients With Type 2 Diabetes: Data From a Randomized, Placebo-Controlled Study.
作者: Kirsten Thiele.;Matthias Rau.;Julian Grebe.;Niels-Ulrik Korbinian Hartmann.;Ertunc Altiok.;Michael Böhm.;András P Keszei.;Nikolaus Marx.;Michael Lehrke.
来源: Circ Cardiovasc Imaging. 2023年16卷4期e015176页 215. Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial.
作者: Moritz J Hundertmark.;Amanda Adler.;Charalambos Antoniades.;Ruth Coleman.;Julian L Griffin.;Rury R Holman.;Hanan Lamlum.;Jisoo Lee.;Daniel Massey.;Jack J J J Miller.;Joanne E Milton.;Shveta Monga.;Ferenc E Mózes.;Areesha Nazeer.;Betty Raman.;Oliver Rider.;Christopher T Rodgers.;Ladislav Valkovič.;Eleanor Wicks.;Masliza Mahmod.;Stefan Neubauer.
来源: Circulation. 2023年147卷22期1654-1669页
Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have emerged as a paramount treatment for patients with heart failure (HF), irrespective of underlying reduced or preserved ejection fraction. However, a definite cardiac mechanism of action remains elusive. Derangements in myocardial energy metabolism are detectable in all HF phenotypes, and it was proposed that SGLT2i may improve energy production. The authors aimed to investigate whether treatment with empagliflozin leads to changes in myocardial energetics, serum metabolomics, and cardiorespiratory fitness.
216. Letter by Kambic et al Regarding Article, "A Randomized, Controlled Trial of Resistance Training Added to Caloric Restriction Plus Aerobic Exercise Training in Obese Heart Failure With Preserved Ejection Fraction".217. Effects of Atrial Fibrillation Screening According to N-Terminal Pro-B-Type Natriuretic Peptide: A Secondary Analysis of the Randomized LOOP Study.
作者: Lucas Yixi Xing.;Søren Zöga Diederichsen.;Søren Højberg.;Derk W Krieger.;Claus Graff.;Ruth Frikke-Schmidt.;Morten S Olesen.;Axel Brandes.;Lars Køber.;Ketil Jørgen Haugan.;Jesper Hastrup Svendsen.
来源: Circulation. 2023年147卷24期1788-1797页
Research suggests NT-proBNP (N-terminal pro-B-type natriuretic peptide) to be a strong predictor of incident atrial fibrillation (AF) and stroke. However, its utility in AF screening remains unknown. The aim of this study was to investigate NT-proBNP as a potential marker for screening efficacy with respect to AF yield and stroke prevention.
218. Association Between Hemoglobin Levels and Efficacy of Intravenous Ferric Carboxymaltose in Patients With Acute Heart Failure and Iron Deficiency: An AFFIRM-AHF Subgroup Analysis.
作者: Gerasimos Filippatos.;Piotr Ponikowski.;Dimitrios Farmakis.;Stefan D Anker.;Javed Butler.;Vincent Fabien.;Bridget-Anne Kirwan.;Iain C Macdougall.;Marco Metra.;Giuseppe Rosano.;Frank Ruschitzka.;Peter van der Meer.;Sandra Wächter.;Ewa A Jankowska.; .
来源: Circulation. 2023年147卷22期1640-1653页
Iron deficiency, with or without anemia, is an adverse prognostic factor in heart failure (HF). In AFFIRM-AHF (a randomized, double-blind placebo-controlled trial comparing the effect of intravenous ferric carboxymaltose on hospitalizations and mortality in iron-deficient subjects admitted for acute heart failure), intravenous ferric carboxymaltose (FCM), although having no significant effect on the primary end point, reduced the risk of HF hospitalization (hHF) and improved quality of life versus placebo in iron-deficient patients stabilized after an acute HF (AHF) episode. These prespecified AFFIRM-AHF subanalyses explored the association between hemoglobin levels and FCM treatment effects.
219. Randomized Trial of Stand-Alone Use of the Antimicrobial Envelope in High-Risk Cardiac Device Patients.
作者: Christopher R Ellis.;Arnold J Greenspon.;John A Andriulli.;Paul A Gould.;Roger G Carillo.;Matthew J Kolek.;Rachel Donegan.;Ansel P Amaral.;Suneet Mittal.
来源: Circ Arrhythm Electrophysiol. 2023年16卷5期e011740页
Cardiac implantable electronic device (CIED) infection has a high mortality. Previous investigations showed reduced postoperative infections using skin preparation with chlorhexidine, preoperative intravenous antibiotics, and a TYRX-a antibacterial envelope. The additional benefit of antibiotic pocket wash and postoperative antibiotics has not been systematically studied.
220. Effectiveness of the Family Heart Talk Communication Tool in Improving Family Member Screening for Dilated Cardiomyopathy: Results of a Randomized Trial.
作者: Daniel D Kinnamon.;Elizabeth Jordan.;Garrie J Haas.;Mark Hofmeyer.;Evan Kransdorf.;Gregory A Ewald.;Alanna A Morris.;Anjali Owens.;Brian Lowes.;Douglas Stoller.;W H Wilson Tang.;Sonia Garg.;Barry H Trachtenberg.;Palak Shah.;Salpy V Pamboukian.;Nancy K Sweitzer.;Matthew T Wheeler.;Jane E Wilcox.;Stuart Katz.;Stephen Pan.;Javier Jimenez.;Keith D Aaronson.;Daniel P Fishbein.;Frank Smart.;Jessica Wang.;Stephen S Gottlieb.;Daniel P Judge.;Charles K Moore.;Jonathan O Mead.;Gordon S Huggins.;Hanyu Ni.;Wylie Burke.;Ray E Hershberger.; .
来源: Circulation. 2023年147卷17期1281-1290页
Managing disease risk among first-degree relatives of probands diagnosed with a heritable disease is central to precision medicine. A critical component is often clinical screening, which is particularly important for conditions like dilated cardiomyopathy (DCM) that remain asymptomatic until severe disease develops. Nonetheless, probands are frequently ill-equipped to disseminate genetic risk information that motivates at-risk relatives to complete recommended clinical screening. An easily implemented remedy for this key issue has been elusive.
|